Novo Nordisk A/S Common Stock (NVO)

Novo Nordisk reported Q2 sales of $11.7 billion, missing consensus. Sales increased by 13% in Danish kroner, driven by GLP-1 diabetes and obesity care sales.

Tech entrepreneur Bryan Johnson refutes claims that Novo Nordisk AS's Ozempic demonstrates anti-aging properties.

The results follow Novo’s worst weekly decline in its history after the company slashed its full-year guidance.

The U.S. stock market experienced a turbulent start to August 2025, marked by significant declines for several prominent companies. This downturn, following a volatile end to July, has left investors grappling with mixed signals and heightened uncertainty. While the broader market saw a rebound in early August, driven by

Are you brave enough to catch this falling knife?

Management pointed to competitors gaining market share in key product categories.

UBS downgraded Novo Nordisk to ‘Neutral’ from ‘Buy’ with a price target of DKK 340, down from DKK 600.

Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings

The company makes implantable devices for sleep apnea, an area Eli Lilly is marketing its weight-loss drug.

Management told investors to expect slower sales and profit growth in 2025.

Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose.

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

NVO offers dividend investors a strong 3.62% yield, 16.56% growth, and high profitability, backed by solid financial health and growth potential.

The company reiterated its sales outlook for the year, despite coming in with lighter-than-expected second-quarter sales.

This weight loss drugmaker may be significantly undervalued right now.

US stock futures are up on Monday after ending Friday deep in the red, following a disappointing jobs report by Bureau of Labor Statistics.

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health sector. This uptick signals a renewed investor confidence in the pharmaceutical giant and the wider healthcare industry, which has been navigating a complex landscape of regulatory scrutiny, patent expirations,

Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts.

Competition from all sides is causing Novo Nordisk to revise its expectations for 2025.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Zepbound could benefit handsomely if an apparently planned government program is implemented.

There might be a new way for certain users to defray their costs for obesity treatments.